Application: WB, IHC
Clonality: Polyclonal
Host: Rabbit
Reactivity: Human
Protein Description: HERV-H LTR-associating 2
Gene Name: HHLA2
Alternative Gene Name: B7H7
Isotype: IgG
Interspecies mouse/rat: ENSMUSG00000035914: 32%, ENSRNOG00000033608: 33%
Entrez Gene ID: 11148
Uniprot ID: Q9UM44
Buffer: 40% glycerol and PBS (pH 7.2). 0.02% sodium azide is added as preservative.
Storage Temperature: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
Clonality: Polyclonal
Host: Rabbit
Reactivity: Human
Protein Description: HERV-H LTR-associating 2
Gene Name: HHLA2
Alternative Gene Name: B7H7
Isotype: IgG
Interspecies mouse/rat: ENSMUSG00000035914: 32%, ENSRNOG00000033608: 33%
Entrez Gene ID: 11148
Uniprot ID: Q9UM44
Buffer: 40% glycerol and PBS (pH 7.2). 0.02% sodium azide is added as preservative.
Storage Temperature: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
| Cognate Antibody/Antigen for Anti HHLA2 pAb (ATL-HPA055478 w/enhanced validation) | |
| Antigen | PrEST Antigen HHLA2 (ATL-APrEST88691) |
| Documents & Links for Anti HHLA2 pAb (ATL-HPA055478 w/enhanced validation) | |
| Datasheet | Anti HHLA2 pAb (ATL-HPA055478 w/enhanced validation) Datasheet (External Link) |
| Vendor Page | Anti HHLA2 pAb (ATL-HPA055478 w/enhanced validation) at Atlas |
| Documents & Links for Anti HHLA2 pAb (ATL-HPA055478 w/enhanced validation) | |
| Datasheet | Anti HHLA2 pAb (ATL-HPA055478 w/enhanced validation) Datasheet (External Link) |
| Vendor Page | Anti HHLA2 pAb (ATL-HPA055478 w/enhanced validation) |
| Citations for Anti HHLA2 pAb (ATL-HPA055478 w/enhanced validation) – 4 Found |
| HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival. Cancer Lett. 2019 Feb 1;442:333-340. doi: 10.1016/j.canlet.2018.11.007. Epub 2018 Nov 14. PubMed |
| HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma. Oncol Rep. 2019 Dec;42(6):2309-2322. doi: 10.3892/or.2019.7343. Epub 2019 Oct 1. PubMed |
| HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma. J Immunother Cancer. 2020 Jan;8(1):e000157. doi: 10.1136/jitc-2019-000157. PubMed |
| HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma. Front Immunol. 2022 Aug 8;13:902167. doi: 10.3389/fimmu.2022.902167. eCollection 2022. PubMed |